Jaime Sanz1,2, Jacques-Emmanuel Galimard3, Myriam Labopin3, Boris Afanasyev4, Moiseev Ivan Sergeevich4, Emanuele Angelucci5, Nicolaus Kröger6, Yener Koc7, Fabio Ciceri8, J L Diez-Martin9, Mutlu Arat10, Simona Sica11, Montserrat Rovira12,13, Mahmoud Aljurf14, Johanna Tischer15, Bipin Savani16, Annalisa Ruggeri8, Arnon Nagler17, Mohamad Mohty18. 1. Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain. sanz_jai@gva.es. 2. CIBERONC, Instituto Carlos III, Madrid, Spain. sanz_jai@gva.es. 3. EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France. 4. RM Gorbacheva Research Institute, Pavlov University, Lva Tolstogo 6/8, 197022, Saint-Petersburg, Russian Federation. 5. Hematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genova, Italy. 6. Bone Marrow Transplantation Centre, University Hospital Eppendorf, Hamburg, Germany. 7. Medicana International, Istanbul, Turkey. 8. Ospedale San Raffaele s.r.l., Haematology and BMT, Milan, Italy. 9. Hematology Department, Hospital GU Gregorio Marañon, Instituto de Investigación Sanitaria Gregorio Marañon, Universidad Complutense Madrid, Madrid, Spain. 10. Florence Nightingale Sisli Hospital, Hematopoietic SCT Unit, Istanbul, Turkey. 11. Istituto di Ematologia, Universita Cattolica S. Cuore, Rome, Italy. 12. Department of Hematology, Hospital Clinic, Institute of Hematology and Oncology, Barcelona, Spain. 13. August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. 14. King Faisal Specialist Hospital and Research Centre Oncology (Section of Adult Haematolgy/BMT), Riyadh, Saudi Arabia. 15. Department of Internal Medicine III, Grosshadern, LMU, University Hospital of Munich, Munich, Germany. 16. Vanderbilt University Medical Center, Nashville, TN, USA. 17. Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel. 18. Department of Hematology, and INSERM UMRs 938, Hopital Saint Antoine, Sorbonne University, Paris, France.
Abstract
BACKGROUND: There is no information on the impact of donor type in allogeneic hematopoietic stem cell transplantation (HCT) using homogeneous graft-versus-host (GVHD) prophylaxis with post-transplant cyclophosphamide (PTCy) in acute lymphoblastic leukemia (ALL). METHODS: We retrospectively analyzed outcomes of adult patients with ALL in CR1 that had received HCT with PTCy as GVHD prophylaxis from HLA-matched sibling (MSD) (n = 78), matched unrelated (MUD) (n = 94) and haploidentical family (Haplo) (n = 297) donors registered in the EBMT database between 2010 and 2018. The median follow-up period of the entire cohort was 2.2 years. RESULTS: Median age of patients was 38 years (range 18-76). Compared to MSD and MUD, Haplo patients received peripheral blood less frequently. For Haplo, MUD, and MSD, the cumulative incidence of 100-day acute GVHD grade II-IV and III-IV, and 2-year chronic and extensive chronic GVHD were 32%, 41%, and 34% (p = 0.4); 13%, 15%, and 15% (p = 0.8); 35%, 50%, and 42% (p = 0.01); and 11%, 17%, and 21% (p = 0.2), respectively. At 2 years, the cumulative incidence of relapse and non-relapse mortality was 20%, 20%, and 28% (p = 0.8); and 21%, 18%, and 21% (p = 0.8) for Haplo, MUD, and MSD, respectively. The leukemia-free survival, overall survival and GVHD-free, relapse-free survival for Haplo, MUD, and MSD was 59%, 62%, and 51% (p = 0.8); 66%, 69%, and 62% (p = 0.8); and 46%, 44%, and 35% (p = 0.9), respectively. On multivariable analysis, transplant outcomes did not differ significantly between donor types. TBI-based conditioning was associated with better LFS. CONCLUSIONS: Donor type did not significantly affect transplant outcome in patient with ALL receiving SCT with PTCy.
BACKGROUND: There is no information on the impact of donor type in allogeneic hematopoietic stem cell transplantation (HCT) using homogeneous graft-versus-host (GVHD) prophylaxis with post-transplant cyclophosphamide (PTCy) in acute lymphoblastic leukemia (ALL). METHODS: We retrospectively analyzed outcomes of adult patients with ALL in CR1 that had received HCT with PTCy as GVHD prophylaxis from HLA-matched sibling (MSD) (n = 78), matched unrelated (MUD) (n = 94) and haploidentical family (Haplo) (n = 297) donors registered in the EBMT database between 2010 and 2018. The median follow-up period of the entire cohort was 2.2 years. RESULTS: Median age of patients was 38 years (range 18-76). Compared to MSD and MUD, Haplo patients received peripheral blood less frequently. For Haplo, MUD, and MSD, the cumulative incidence of 100-day acute GVHD grade II-IV and III-IV, and 2-year chronic and extensive chronic GVHD were 32%, 41%, and 34% (p = 0.4); 13%, 15%, and 15% (p = 0.8); 35%, 50%, and 42% (p = 0.01); and 11%, 17%, and 21% (p = 0.2), respectively. At 2 years, the cumulative incidence of relapse and non-relapse mortality was 20%, 20%, and 28% (p = 0.8); and 21%, 18%, and 21% (p = 0.8) for Haplo, MUD, and MSD, respectively. The leukemia-free survival, overall survival and GVHD-free, relapse-free survival for Haplo, MUD, and MSD was 59%, 62%, and 51% (p = 0.8); 66%, 69%, and 62% (p = 0.8); and 46%, 44%, and 35% (p = 0.9), respectively. On multivariable analysis, transplant outcomes did not differ significantly between donor types. TBI-based conditioning was associated with better LFS. CONCLUSIONS: Donor type did not significantly affect transplant outcome in patient with ALL receiving SCT with PTCy.
Authors: D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas Journal: Bone Marrow Transplant Date: 1995-06 Impact factor: 5.483
Authors: Arnon Nagler; Myriam Labopin; Ryszard Swoboda; Pietro Pioltelli; Mutlu Arat; Ibrahim Yakoub-Agha; Alexander Kulagin; Anna Maria Raiola; Hakan Ozdogu; Antonio Risitano; Zubeyde Nur Ozkurt; Jaime Sanz; Eolia Brissot; Peric Zina; Sebastian Giebel; Fabio Ciceri; Mohamad Mohty Journal: Hemasphere Date: 2022-10-13
Authors: John A Snowden; Isabel Sánchez-Ortega; Selim Corbacioglu; Grzegorz W Basak; Christian Chabannon; Rafael de la Camara; Harry Dolstra; Rafael F Duarte; Bertram Glass; Raffaella Greco; Arjan C Lankester; Mohamad Mohty; Bénédicte Neven; Régis Peffault de Latour; Paolo Pedrazzoli; Zinaida Peric; Ibrahim Yakoub-Agha; Anna Sureda; Nicolaus Kröger Journal: Bone Marrow Transplant Date: 2022-05-19 Impact factor: 5.174